Search Results - "Dutailly, P."

672P Real-world study of cabozantinib in patients with advanced renal cell carcinoma (aRCC) after VEGF-targeted therapy (CASSIOPE): Interim data for patients who had received prior nivolumab by Procopio, G., Hamberg, P., Bigot, P., Suarez Rodriguez, C., Barthelemy, P., Eymard, J-C., Masini, C., Gajate Borau, P., Dutailly, P., Perrot, V., Staehler, M.

Get full text

730P Interim analysis of CASSIOPE: A real-world study of cabozantinib for the treatment of advanced renal cell carcinoma (aRCC) after VEGF-targeted therapy in Europe by Procopio, G., Hamberg, P., Bigot, P., Suarez, C., Barthélémy, P., Eymard, J-C., Masini, C., Gajate Borau, P., Dutailly, P., Perrot, V., Staehler, M.

Get full text

P192 CaboCombo: interim analyses from an international real-world study assessing the use of cabozantinib plus nivolumab (CaboNivo) as first-line (1L) treatment for advanced Renal Cell Carcinoma (aRCC) by Barthélémy, P., Gimel, P., Bailly, S., Geoffrois, L., Goujon, M., Laramas, M., Park, S.H., Saldana, C., Dutailly, P., Perrot, V., Qvick, B., Bigot, P.

Get full text

C84: Efficacy on testosterone levels of triptorelin pamoate 11.25 mg administered subcutaneously every 3 months in patients with locally advanced or metastatic prostate cancer by Lebret, T, Hublarov, O, Jinga, V, Petkova, L, Kotsev, R, Sinescu, I, Fages, M-E, Pouget, J-C, Dutailly, P

Get full text

S147: Efficacy on testosterone levels of triptorelin pamoate 11.25 mg administered subcutaneously every 3 months in patients with locally advanced or metastatic prostate cancer by Lebret, T, Hublarov, O, Jinga, V, Petkova, L, Kotsev, R, Sinescu, I, Fages, M.E, Pouget, J.C, Dutailly, P

Get full text

Increlex Growth Forum Database (IGFD) Registry 2006–2010: United States and European Union Involvement by Gambetti a, O., Kuntze a, J., Dutailly b, P., Maisonobe b, P., Frane c, J., Howell a, S., Courtney a, J., Bakker a, B.

Get full text